Tissue plasminogen activator and patients with acute ischemic stroke: The litigation landscape

Tissue plasminogen activator and patients with acute ischemic stroke: The litigation landscape

Abstract Objective Tissue plasminogen activator (tPA) is considered standard of care for acute ischemic stroke treatment, but some physicians withhold or delay this highly time‐dependent therapy from stroke patients because they do not think it works well or they are worried about the adverse effect...

Full description

Bibliographic Details
Main Authors: Latha Ganti, Bryan Kwon, Andrew George, Thor Stead, Cherian Plamoottil, Paul Banerjee
Format: Article
Language:English
Published: Elsevier 2022-02-01
Series:Journal of the American College of Emergency Physicians Open
Subjects:
acute ischemic stroke
emergency medicine
litigation
tissue plasminogen activator
Online Access:https://doi.org/10.1002/emp2.12646

Similar Items

Similar Items